Key Takeaways
- A new Expert Committee will make recommendations on what Canada’s single-payer pharmacare program should look like.
- The R&D-based industry says the committee should include an industry representative and that its voice has been overlooked during pharmacare discussions.
- The recent Pharmacare Act provides access to contraceptives and diabetes medicines a the first stage of the pharmacare program.
A newly established Committee of Experts in Canada will make recommendations on how to operate and fund a “national, universal single-payer pharmacare program” for patients in the country
Currently Canada has no single provider of pharmaceuticals, and provincial/territorial and federal drug plans vary across the country. For example, some plans only cover patients receiving social assistance, seniors, or patients with certain conditions, while others take an income-based approach. In addition, there are also variations on levels of co-payments
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?